CureVac and GSK COVID-19 vaccine shows promise in pre-clinical study
CureVac and GSK's second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response in a pre-clinical study.
List view / Grid view
CureVac and GSK's second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response in a pre-clinical study.
A new study has identified a vital enzyme, known as APOBEC3A, that could lead to new treatments against cancers and viral infections.
Fenofibrate and its active form, fenofibric acid, have been shown to significantly reduce COVID-19 infection in human cells.
Researchers have been using artificial intelligence to study how the microbiome interacts with the human system to improve vaccine response.
In this article, Dr Jon Volmer and Dr Jon Lenn discuss a new approach to formulation models to test drug delivery based on reconstituted nasal epithelium.
NICEdrug.ch is an open-access database that may help scientists assess potential drugs for a range of diseases more quickly.
Scientists from the University of Chicago discovered that the drug masitinib inhibits the replication of SARS-CoV-2 in mice.
Listen to this podcast to discover how SARS-CoV-2 variants are sequenced and why PCR assays could provide an alternative for resource-constrained places.
A new “atlas” has been created in the US that charts how 152 different antibodies attack the SARS-CoV-2 Spike protein.
A new computer algorithm has identified highly conserved sequences in viral proteins that could make the best drug targets for COVID-19.
Researchers in Germany have identified 69 small molecules as binding partners for genomic RNA of SARS-CoV-2, possibly leading to new drugs.
Professor Christian Brechot explains why lentiviral vectors could serve as an effective tool for treating a wide range of cancers and could be used for vaccines.
Researchers have developed a 3D “assembloid” that presents a potential entry route of COVID-19 into the brain.
Researchers have identified 38 drugs that could be repurposed to treat COVID-19 through a strategy involving virtual screening and cell-based assays.
Researchers in Australia have discovered a new site on the COVID-19 Spike protein that could be targeted by an anticoagulant drug.